Thomas Bannister, PhD

Scientific Director, Sr
Affiliated Faculty, Department of Chemistry
Department of Molecular Medicine
Florida Campus


 Email

Scripps Research Joint Appointments

Affiliated Faculty, Department of Chemistry
Founding member, Medicinal Chemistry

Other Joint Appointments

Past Chair, Medicinal Chemistry Division of the American Chemical Society (2014-16)
Long-range planning committee, MEDI Division of the ACS (2009-11, 2014-16)

Research Focus

Organic/Medicinal Chemistry and Drug Discovery

The discovery of possible drug candidates is a highly collaborative endeavor, with medicinal chemistry as a core, problem-solving component. My major research efforts are joint projects with world experts in cancer biology and neuroscience, wherein my group provides the organic and medicinal chemistry expertise and drug design insights. In general, we strive to find novel ways to target poorly-treated, common, and devastating disorders that increasingly burden world health care systems.

Neuroscience studies include:

  • Biased mu opioid agonists, aiming for a holy grail of sorts: to separate the robust pain relief provided by opiates from their many unwanted side effects. This collaboration with Laura Bohn's group has led to findings published in 2017 in Cell, with follow-up chemistry disclosure in the Journal of Medicinal Chemistry in late 2018 (featured on the cover).
  • NOP agonists, for post-traumatic stress disorder (PTSD) and alcohol addiction relapse therapy.
  • NAD-elevating neuroprotectants, for Alzheimer’s and Parkinson’s Diseases, and for ALS.

Cancer projects include:

  • KLF5 inhibitors for colorectal cancer therapy.
  • TBK1 and IKKi dual kinase inhibitors, for hormone-refractory prostate cancer.
  • Inhibitors of kinases CK1delta, ASK1, and ULK1, for various cancers.
  • Modulators of the HIPPO-YAP pathway, for various cancers.

Other exploratory efforts include:

  • High-throughput screening-based "chemical probe development", seeking first-in-class small molecules for investigating the therapeutic potential of new target proteins.
  • Probe development efforts encompass multiple therapeutic areas, including treatments for cancers, glaucoma, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), addiction, infectious diseases, and mood disorders.
One chemical probe effort targets the orphan GPCR GPR151, a target that may be relevant for the development of treatments for addiction, depression, and schizophrenia.The discovery of possible drug candidates is a highly collaborative endeavor, with medicinal chemistry as a core, problem-solving component.  Our major efforts are thus joint projects with world experts in cancer biology and neuroscience, wherein our group provides the organic and medicinal chemistry expertise. 

Our cancer projects target unique metabolic phenotypes of tumor cells, identifying defining molecular characteristics to be exploited for the development of targeted therapies. Most tumor types have a shared reliance upon active transport of nutrients and building blocks to drive rapid cancer cell growth and to sustain survival. They also largely rely upon glycolysis for ATP production (the Warburg effect). As examples, we have created molecules to keep tumor cells from exporting lactate, the end product of glycolysis.  We have also designed compounds to block amino acid transporters that are up-regulated by many tumors. We have a program targeting expression of a transcription factor that drives colon cancer progression. We also have a number of kinase inhibitor programs aimed the discovery of treatments for brain cancers, triple-negative breast cancer, hormone-resistant prostate cancer, and perhaps other forms as well.  This are collaborative efforts with top TSRI cancer biologists including Derek Duckett, Joseph Kissil, Jun-li Luo, and also including John Cleveland from the Moffitt Cancer Center.

Many of our anticancer programs have a computational chemistry-directed focus, relying on molecular modeling based upon published coordinates, virtual screening, scoring, and validation of predicted hits through chemical synthesis. We use the Schrodinger suite of modeling software in these studies.  For future work we may have a need to hire postdoctoral scientists with both computational and synthesis experience.  Please contact me for further information. 

In our neuroscience studies we are developing GPCR agonists that have targeted effects in the brain.  We are exploring GPCR signaling bias in mu opioid receptor activation, aiming for a holy grail of sorts: to separate the robust pain relief provided by opiates from their many unwanted side effects. This collaboration with Laura Bohn's group has led to pain relievers that seem to be devoid of many of the side effects of morphine and related opiates, such as respiratory suppression, heart rate effects, and GI effects (constipation). In a separate study we identified tool compound with promise in an animal model of post-traumatic stress disorder (PTSD).

Other exploratory efforts use medicinal chemistry in concert with high-throughput screening or following HTS campaigns, where we seek to discover and optimize "chemical probes", or first-in-class small molecules that should prove useful for investigating the therapeutic potential of new target proteins.  Such probe development efforts encompass multiple therapeutic areas, including treatments for ALS, Parkinson's Disease, addiction, infectious diseases,  cancers, glaucoma, and mood disorders.  

One such chemical probe effort, a collaboration with Patsy McDonald, targets the orphan GPCR GPR151, a target that may be relevant for the development of treatments for addiction, depression, and schizophrenia.  In a collaboration with Sathya Puthanveettil we are investigating the potential of facilitating the function of kinesin motor proteins as a novel approach to therapies for Alzheimer’s disease (AD) and frontal temporal dementia (FTD), which are poorly-treated, common, and devastating disorders that increasingly burden world health care systems. In a collaboration with Corinne Lasmezas, we are developing compounds that rescue neurons from toxicity of protein aggregates, relevant for developing new therapies for ALS and Parkinson's Disease. 

As you can tell, collaborative drug discovery research is order of the day in my lab!

Members of my group benefit from interactions not only with other chemists but with top biologists and pharmacologists, as they partake in project team meetings as well as in our weekly chemistry group meetings. My research is funded currently by 8 NIH grants on which I am a co-principal investigator and 8 others NIH grants where I am a named investigator or co-investigator.

On occasion I have openings for outstanding postdoctoral fellows in my labs.  As mentioned above, an especially good fit would be a postdoc with lab synthesis experience and with prior expertise in using the Schrodinger suite of molecular modeling software, to aid our virtual screening-based efforts.  Our postdoctoral scientists collaborate with a team of biological co-investigators, applying knowledge and experience in modern organic, heterocyclic, and/or medicinal chemistry toward an ongoing drug discovery effort. Excellent communication skills, good synthetic organic chemistry laboratory skills, ability to work in the US, and familiarity with modern synthetic techniques and instrumentation are required in this role.  Contact me for further details.

active grants & grant ID
  R01DA033073
  R01NS103195
  R01CA223823
  R01CA227073
  R01DA046204
  R01CA221948
  R01AG060038
  R21NS105941
  R01RCA197944A
  R01DA042746
  R33AI119043
  R01MH110441
  R01DA038964
  R01GM122109
  R01RMH111116A
  RF1AG060038

grant ID

  R01DA033073

  R01NS103195

  R01CA223823

  R01CA227073

  R01DA046204

  R01CA221948

  R01AG060038

  R21NS105941

R   R01RCA197944A

  R01DA042746

R33AI119043

  R01MH110441

  R01DA038964

   R01GM122109

R   R01RMH111116A

  RF1AG060038


Education

Ph.D. (Organic Chemistry), Indiana University, 1991
M.Phil. Master of Philosophy, Yale University, 1987
A.B. (Chemistry), Wabash College, 1984

Professional Experience

2005-2017 Assistant Professor of Chemistry (Joint Appointment), Chemistry, Scripps Research

Awards & Professional Activities

2008-2010: Member, Long Range Planning Committee (LRPC), Medicinal Chemistry Division of the ACS
2015: Chair, ACS Medicinal Chemistry Long Range Planning Committee (a nationally elected position)
2016: Chair, ACS Medicinal Chemistry Division (a nationally elected position)


Selected References

All Publications

I have authored in total over 95 published patents and peer-reviewed journal articles related to drug discovery and medicinal/organic chemistry.  

 

An on-line list of many of my peer-reviewed pubmed-indexed publications can be found at the following url:  https://www.ncbi.nlm.nih.gov/pubmed/?term=Bannister+T.+D.%5Bau%5D

Selected journal publications since
 2015 include: 

1.      A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Grim, T. W.; Schmid, C. L.; Stahl, E. L.; Pantouli, F.; Ho, J-H.; Acevedo-Canabal, A.; Kennedy, N. M.; Cameron, M. D.; Bannister, T. D.; Bohn, L. M. Nature Neuropsycopharmacology, 2019, published online ahead of print Aug 23, 2019 at the following link: https://www.nature.com/articles/s41386-019-0491-8

2.       The novel small molecule SR18662 efficiently inhibits the growth of colorectal cancer in vitro and in vivo. Kim, J.; Wang, C.; de Sabando, A. R.; Cole, H. L.; Huang, T. J.; Yang, J.; Bannister, T. D.; Yang, V. W.; Bialkowska, A. B. Mol. Cancer Therapeutics, 2019, DOI: 10.1158/1535-7163.MCT-18-1366, epub ahead of print: https://mct.aacrjournals.org/content/early/2019/07/27/1535-7163.MCT-18-1366

3.    Native Directed Site-Selective δ-C(sp3)–H and δ-C(sp2)–H Arylation of Primary Amines. Lin, H.; Pan, X.; Barsamian, A.; Kamenecka, T. M.; Bannister, T. D. ACS Catal., 2019, 9, 4887–4891.

4.    Inhibitors of Lactate Transport: A Promising Approach in Cancer Drug Discovery. Bannister, T. D. 2019, In: Boffetta, P., Hainaut, P. (Eds.), Encyclopedia of Cancer, 3rd edition, vol. 2, Elsevier, Academic Press, pp. 266–278. http://dx.doi.org/10.1016/B978-0-12-801238-3.64996-6

5.      Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. Kennedy, N. M.; Schmid, C. L.; Lovell, K. M.; Yue, Z.; Chen, Y-T.; Cameron, M. D.; Bohn, L. M.; Bannister, T. D. J. Med Chem., 2018, 61, 19, 8895-8907.

6.    Chemical Validation and Optimization of Pharmacoperones Targeting Vasopressin Type Two Receptor Mutant. Janovick, J. A.; Spicer, T. P.; Bannister, T. D.; Smith, E.; Ganapathy, V.; Scampavia, L. Biochem J. 2018, 475(18), 2941-2953.

7.    A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa. Collia, D.; Bannister, T. D.; Tan, H.; Jin, S.; Langaee, T.; Shumate, J.;  Scampavia, L.;  Spicer, T. P. SLAS Discov. 2018, (1):55-64. doi: 10.1177/2472555217728489. Epub 2017 Aug 29. PMID: 28850797

8.    Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Nieto, A.; Fernández-Vega, V.; Spicer, T. P.; Sturchler, E.; Adhikari, P.; Kennedy, N.; Mandat, S.; Chase, P.; Scampavia, L.; Bannister, T.; Hodder, P.; McDonald, P. H. Assay Drug Dev Technol. 2018, 16(5):278-288. PMID: 30019946

9.    Site-​selective γ-​C(sp3)​-​H and γ-​C(sp2)​-​H arylation of free amino esters promoted by a catalytic transient directing group. Lin, H.; Wang, C.; Bannister, T. D.; Kamenecka, T. M. Chemistry - A European Journal (2018), 24(38), 9535-9541.

10.  Bias factor and therapeutic window correlate to predict safer opioid analgesics. Schmid, C. L., Kennedy, N. M.; Ross, N. C.; Lovell, K. M.; Yue, Z.; Morgenweck, J.; Cameron, M. D., Bannister, T. D.; Bohn, L. M. Cell, 2017, 171(5):1165-1175. PMID: 29149605.

11.  Natural Product Synthesis and Drug Discovery: Shortcomings and Successes. Pedzisa, L., Bannister, T. D. Trop J Nat Prod Res, September 2017; 1(3):95-96.

12.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. Janovick, J. A.; Spicer, T. P.; Bannister, T. D.; Scampavia, L.; Conn, P. M. PLoS One, 2017, 12(8):e0181830. PMID: 28767678.

13.  SR-18662: A Potent Colorectal Cancer Growth Inhibitor, Kim, J. M.; Huang, T. J.; de Sabando, A. R.; Yang, V. W.; Bialkowska, A.; Bannister T. D.; Wang, C. Gastroenterology 2017, 152(5):S41.

14.  Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Madoux, F.; Dreymuller, D.;  Pettiloud, J. P.;  Santos, R.;  Becker-Pauly, C.; Ludwig, A.;  Fields, G. B.;  Bannister, T.; Spicer, T. P.;  Cudic, M.;  Scampavia, L. D.;  Minond, D. Sci Rep. 2016 6(1):11. doi: 10.1038/s41598-016-0013-4. PMID: 28442704

15.  Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus. Smith, E.; Janovick, J. A.; Bannister, T. D.; Shumate, J.; Scampavia, L.; Conn, P. M.; Spicer, T. P. J Biomol Screen. 2016, 8:824-831. PMID: 27280550.

16.  Receptor antagonism/agonism can be uncoupled from pharmacoperone activity. Janovick J. A.; Spicer T. P.; Smith, E.; Bannister, T. D.; Kenakin, T.; Scampavia, L.; Conn, P. M. Mol Cell Endocrinol. 2016 ;434:176-85. PMID: 27389877

17.  Synthesis and Cytoxicity of Sempervirine and Analogues. Pan, X.; Yang, C.; Cleveland, J. L, Bannister, T. D. Journal of Organic Chemistry 2016, 81(5), 2194-2200.

18.  Tale of Two Protecting Groups—Boc vs SEM—for Directed Lithiation and C–C Bond Formation on a Pyrrolopyridazinone Core, Nair, R. N., Bannister, T. D. Org. Process Res. Dev., 2016, 20 (7), 1370–1376.

19.  Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Nair, R. N.; Mishra, J. K.; Li, F.; Tortosa, M.; Yang, C.; Doherty, J. R.; Cameron, C.; Cleveland, J. L.; Roush, W. R.; Bannister, T. D. Med. Chem. Commun. 2016, 7(5), 900-905.

20.  ML264 - a novel small-molecule compound that potently inhibits growth of colorectal cancer. de Sabando, A. R.; Wang, C.; He, Y.; García-Barros, M.; Kim, J.; Shroyer, K. R.; Bannister, T. D.; Yang, V. W.; B. Bialkowska, A. B. Molecular Cancer Therapeutics, 2016, 15(1), 72-83. The article may be accessed at: http://mct.aacrjournals.org/content/early/2015/11/26/1535-7163.MCT-15-0600.abstract

21.  Identification of Small Molecules that Disrupt Signaling between ABL and Its Positive Regulator RIN1. Ting, P. Y., Damoiseaux, R.; Titz, B.; Bradley, K. A.; Graeber, T. G.; Fernández-Vega, V.; Bannister, T.D.; Chase, P.; Nair, R.; Scampavia, L.; Hodder, P.; Spicer, T. P.; Colicelli, J. PLoS One 2015, 10(3): e0121833. doi:10.1371 /journal.pone.0121833

22.  Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors. Abdul-Hay, S. O.; Bannister, T. D.; Wang, H.; Cameron, M. D.;  Caulfield, T. R., Masson, A.; Bertrand, J.; Howard, E. A.; McGuire, M. P.; Crisafulli, U.; Rosenberry, T. R.; Topper, C. L.; Thompson, C. R.; Schürer, S. C.; Madoux, F.; Hodder, P.; Leissring, M. A. ACS Chem Biol. 2015,10(12):2716-24. doi: 10.1021/acschembio.5b00334. PMID: 26398879

23.  One-Pot Directed Alkylation/Deprotection Strategy for the Synthesis of Substituted Pyrrole[3,4-d]pyridazinones. Nair, R. N.; Bannister, T. D. Eur. J. Org. Chem. 2015, 1764–1770.

24.  Preparation of tetrasubstituted pyrimido[4,5-d]pyrimidine diones. Wang, H.; Wang, C.; Bannister, T. D. Tetrahedron Lett. 2015, 56 (15), 1949–1952.

25.  Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNS Synthestase via High-Throughput Orthogonal Screening. Pedro-Rosa, L.: Buckner, F. S.; Ranade, R. M.; Eberhardt, C.; Madoux, F.; Gillespie, J. R., Koh, C. Y., Brown, S., Lohse, J., Verlinde, C. L. M., Fan, E., Bannister, T., Scampavia, L., Hol, W. M. G.; Spicer, T.; Hodder, P. J. Journal of Biomolecular Screening 2015, 20(1), 122–130.

1.    Bias factor and therapeutic window correlate to predict safer opioid analgesics. Schmid, C. L., Kennedy, N. M.; Ross, N. C.; Lovell, K. M.; Yue, Z.; Morgenweck, J.; Cameron, M. D., Bannister, T. D.; Bohn, L. M. Cell, 2017, 171(5):1165-1175. PMCID: PMC5731250.

 

2.    Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. Janovick JA, Spicer TP, Bannister TD, Scampavia L, Conn PM. PLoS One,  2017 Aug 2;12(8):e0181830. doi: 10.1371/journal.pone.0181830. eCollection 2017. PMID: 28767678.

 

3.    SR-18662: A Potent Colorectal Cancer Growth Inhibitor, Julie M. Kim, Timothy J. Huang, Ainara Ruiz de Sabando, Vincent W. Yang, Agnieszka Bialkowska, Thomas D. Bannister, Chao Wang, Gastroenterology 2017, 152(5):S41.

 

4.    Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus, Smith E, Janovick JA, Bannister TD, Shumate J, Scampavia L, Conn PM, Spicer TP.,  J Biomol Screen. 2016 Jun 8. pii: 1087057116653925. [Epub ahead of print], PMID: 27280550.

 

5.    Synthesis and Cytoxicity of Sempervirine and Analogues. Pan, X.; Yang, C.; Cleveland, J.L, Bannister, T.D. Journal of Organic Chemistry 2016, 81(5), 2194-2200.

 

6.    Tale of Two Protecting Groups—Boc vs SEM—for Directed Lithiation and C–C Bond Formation on a Pyrrolopyridazinone Core, Nair, R.N., Bannister, T.D. Org. Process Res. Dev., 2016, 20 (7), 1370–1376.

 

7.    Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Nair, R. N.; Mishra, J. K.; Li, F.; Tortosa, M.; Yang, C.; Doherty, J. R.; Cameron, C.; Cleveland, J. L.; Roush, W. R.; Bannister, T. D. Med. Chem. Commun. 2016, 7(5), 900-905.

 

8.    ML264 - a novel small-molecule compound that potently inhibits growth of colorectal cancer. de Sabando, A. R.; Wang, C.;  He, Y.; García-Barros, M.; Kim, J.; Shroyer, K. R.; Bannister, T. D.; Yang, V. W.; B. Bialkowska, A. B. Molecular Cancer Therapeutics, 2016, 15(1), 72-83. The article may be accessed at: http://mct.aacrjournals.org/content/early/2015/11/26/1535-7163.MCT-15-0600.abstract

 

9.    Identification of Small Molecules that Disrupt Signaling between ABL and Its Positive Regulator RIN1. Ting, P. Y., Damoiseaux, R.; Titz, B.; Bradley, K. A.; Graeber, T. G.; Fernández-Vega, V.; Bannister, T.D.; Chase, P.; Nair, R.; Scampavia, L.; Hodder, P.; Spicer, T.P.; Colicelli, J. PLoS One 2015, 10(3): e0121833. doi:10.1371 /journal.pone.0121833

 

10.  One-Pot Directed Alkylation/Deprotection Strategy for the Synthesis of Substituted Pyrrole[3,4-d]pyridazinones. Nair RN, Bannister TD. Eur. J. Org. Chem. 2015, 1764–1770.

 

11.  Preparation of tetrasubstituted pyrimido[4,5-d]pyrimidine diones. Wang H, Wang C, Bannister TD. Tetrahedron Lett. 2015, 56 (15), 1949–1952.

12.  Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNS Synthestase via High-Throughput Orthogonal Screening. Pedro-Rosa, L., Buckner, F.S., Ranade, R.M., Eberhardt, C., Madoux, F., Gillespie, J.R., Koh, C.Y., Brown, S., Lohse, J., Verlinde, C.L.M., Fan, E., Bannister, T., Scampavia,  L., Hol, W.M.G., Spicer, T., & Hodder, P. J. Journal of Biomolecular Screening 2015, 20(1), 122–130.

13.  Synthesis and Structure-Activity Relationships of Pteridine Dione and Trione Monocarboxylate Transporter 1 Inhibitors, Wang H, Bannister, TD. Journal of Medicinal Chemistry 2014, 57 (17), 7317–7324.

14.  Sequential Sonagashira and Larock Indole Synthesis Reactions in a General Strategy To Prepare Biologically Active β-Carboline-Containing Alkaloids. Pan X, Bannister TD. Organic Letters 2014, 16(23), 6124–6127.

15.  Grubbs Cross-Metathesis Pathway for a Scalable Synthesis of gamma-keto alpha,beta- unsaturated Esters.  Nair R, Bannister, TD.  J. Org. Chem. 2014, 79 (3), 1467–1472.

16.  Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis. Doherty JR, Yang C, Scott KEN, Michael Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Yungi L, Dang CV, K. Kumar KG, Butler AA, Bannister TD,  Hooper AT, Unsal-Kacmaz K, Roush WR and Cleveland JL. Cancer Research 2014, 74, 908-920.

17.  Hydroxyquinoline-derived compounds and analoging of selective MCL-1 inhibitors using a functional biomarker. David J. Richard, Ryan Lena, Noel Blake, William E. Pierceall, Nicole E. Carlson, Thomas Bannister, Christina Eberhart Keller, Marcel Koenig, Yuanjun He, Dmitriy Minond, Jitendra Mishra, Timothy Spicer, Michael Cameron, Peter Hodder, and Michael H. Cardone. Bioorg. Med. Chem. Lett., 2013, 21, 6642-6649.

18.  Amygdala-Dependent Fear Is Regulated by Oprl1 in Mice and Humans with PTSD.  Andero R, Brothers SP, Jovanoviv T, Chen YT, Salah-Uddin H, Cameron M, Bannister TD, Almli L, Stevens JS, Bradley B, Bonder EB, Wahlestedt C, Ressler KJ. Science Translational Medicine, 2013, 5 (188), p. 188ra73, online in advance of print: http://stm.sciencemag.org/content/5/188/188ra73.

19.  Amino acid derived quinazolines as Rock/PKA inhibitors. Chowdhury S, Chen YT, Fang X, Grant W, Pocas J, Cameron MD, Ruiz C, Lin L, Park H, Schröter T, Bannister TD, Lograsso PV, Feng Y. Bioorg. Med. Chem. Lett., 2013, 23(6):1592-9.

20.  ML264: An Antitumor Agent that Potently and Selectively Inhibits Krüppel-like Factor Five (KLF5) Expression: A Probe for Studying Colon Cancer Development and Progression. Agnieszka Bialkowska, Melissa Crisp, Franck Madoux, Tim Spicer, Ania Knapinska, Becky Mercer, Thomas D. Bannister, Yuanjun He, Sarwat Chowdhury, Michael Cameron, Vincent W. Yang, and Peter Hodder.  Probe Reports from the NIH Molecular Libraries Program [Internet], March 7, 2013, http://www.ncbi.nlm.nih.gov/books/NBK143546/

21.  ML328: A Novel Dual Inhibitor of Bacterial AddAB and RecBCD Helicase-nuclease DNA Repair Enzymes. TD Bannister, R Nair, T Spicer, V Fernandez Vega, C Eberhart, BA Mercer, M Cameron, S Schurer, SK Amundsen, A Karabulut, LM Londoño, GR Smith, and P Hodder. Probe Reports from the NIH Molecular Libraries Program [Internet], April 5, 2013, http://www.ncbi.nlm.nih.gov/books/NBK148492/

22.  ML311: A Small Molecule that Potently and Selectively Disrupts the Protein-Protein Interaction of Mcl-1 and Bim: A Probe for Studying Lymphoid Tumorigenesis. Thomas Bannister, Marcel Koenig, Yuanjun He, Jitendra Mishra, Tim Spicer, Dmitriy Minond, Adrian Saldanha, Becky A. Mercer, Michael Cameron, Ryan Lena, Nicole Carlson, David Richard, Michael Cardone, and Peter Hodder. Probe Reports from the NIH Molecular Libraries Program [Internet], March 14, 2013, http://www.ncbi.nlm.nih.gov/books/NBK143557/

23.  ML345: A Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE). TD Bannister, H Wang, SO Abdul-Hay, A Masson, F Madoux, J Ferguson, BA Mercer, S Schurer, A Zuhl, BF Cravatt, MA Leissring, and P Hodder.  Probe Reports from the NIH Molecular Libraries Program [Internet], April 5, 2013, http://www.ncbi.nlm.nih.gov/books/NBK148499/


Links

Safer pain relievers from the Bohn and Bannister labs

Bannister Lab Receives Funding to Develop New PTSD Treatments

Scientists Win $2 Million to Identify Potential New Treatments for Schizophrenia and Depression

Scripps Florida Scientists Awarded $3 Million to Develop New, More Effective Pain Treatments

Scripps Florida Scientist Awarded $700,000 to Develop New Treatments for Cocaine Addiction

A Lab with a View: Tom Bannister Looks for Potential New Drugs